New market research titled “Women Infertility - Pipeline Review, H2 2015” is the latest addition to its store. The report provides an overview of the Women Infertility’s therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies profile: AbbVie Inc., Addex Therapeutics Ltd, Allergan Plc, AlphaMab Co., Ltd, APAvadis Biotechnologies Srl, ASKA Pharmaceutical Co., Ltd., Astellas Pharma Inc., Bayer AG, BIOCAD, Dong-A Socio Group, Dongkook Pharmaceutical Co., Ltd., ElexoPharm GmbH, EndoCeutics, Inc., Enteris BioPharma, Inc., Euroscreen S.A., Evotec AG, Ferring International Center S.A., Finox AG, Forendo Pharma Limited, GlaxoSmithKline Plc, Glycotope GmbH, Kissei Pharmaceutical Co., Ltd., Lipicard Technologies Limited, Merrion Pharmaceuticals Plc, Nippon Shinyaku Co., Ltd., Nora Therapeutics, Inc., ObsEva SA, Orphagen Pharmaceuticals, Inc., Pantec Biosolutions AG, PharmaEssentia Corporation, Philogen S.p.A., Reliance Life Sciences Pvt. Ltd., Repros Therapeutics Inc., SK Chemicals Co., Ltd., Takeda Pharmaceutical Company Limited, TocopheRx, Inc., Trophogen, Inc., ValiRx Plc, Viteava Pharmaceuticals, Inc. and Zydus Cadila Healthcare Limited
Drug profiles’: (anastrozole + levonorgestrel), acolbifene hydrochloride + prasterone + GnRH agonist, AKP-501, ASP-1707, barusiban, BAY-1128688, bentamapimod, Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis, Biosimilar 5 for Infertility, Biosimilar 6 for Infertility, Biosimilar 7 for Infertility and Oncology, choriogonadotropin alfa, DKF-301, DKF-304, Drug to Inhibit C-Jun for Endometriosis, Drugs for Endometriosis, Drugs for Endometriosis and Uterine Fibroids, elagolix sodium, epelsiban besylate, ESN-364, EVE-104, FE-999310, follitropin alfa, follitropin alfa (recombinant), follitropin delta, FP-5677, FSH-GEX, kisspeptin-54, KLH-2109, KN-015, leuprolide acetate, LM-001, LM-002, LT-6121, menotropins, MER-104, MIA-602, Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility, Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis, NCE-403, NS-580, NT-100, OBE-001, PEG-FSH, Peptides for Cancer and Endometriosis, Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis, PGL-1001, PGL-2001, Progesterone Second Generation, Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome, Recombinant Protein to Agonize Luteinizing Hormone for Infertility, relugolix, RTPR-013, S-hCG, SKI-2670, Small Molecule to Antagonize FSH Receptor for Women's Health, Small Molecules for Female Infertility, Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology, Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis, Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease, Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis, Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers, Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis, SR-16234, STI-2833, Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology, telapristone acetate, Tetravil, TOP-001, TOP-002, TR-4401, triptorelin, VAL-201, vilaprisan, VPE-001 and VPEA-004
Complete report on H2 2015 pipeline review of Women Infertility with 103 market data tables and 16 figures, spread across 361 pages is available at http://www.rnrmarketresearch.com/women-infertility-pipeline-review-h2-2015-market-report.html .
This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects.
Scope of this report:
· The report provides a snapshot of the global therapeutic landscape of Women Infertility
· The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
· The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects
· The report summarizes all the dormant and discontinued pipeline projects
· A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
· Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
· A detailed assessment of monotherapy and combination therapy pipeline projects
· Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type
· Latest news and deals relating related to pipeline products
Inquire more about this report @ www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=459957 .
Reasons to buy:
· Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
· Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
· Develop strategic initiatives by understanding the focus areas of leading companies
· Identify and understand important and diverse types of therapeutics under development for Women Infertility
· Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
· Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics
· Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
· Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline